ClinicalTrials.gg
Not yet recruitingNCT07947147Updated Nov 18, 2026

Thread Embedding Acupuncture Added to Antihistamine Treatment for Chronic Urticaria

An interventional study of Polydioxanone Thread Embedding Acupuncture and Sham Thread Embedding Acupuncture in Chronic Spontaneous Urticaria, sponsored by University of Medicine and Pharmacy at Ho Chi Minh City. Not yet recruiting at 3 sites in Vietnam. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Medicine and Pharmacy at Ho Chi Minh City · Not applicable, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will test whether adding thread embedding acupuncture to an antihistamine helps adults with chronic hives whose symptoms remain bothersome despite taking the antihistamine. In thread embedding acupuncture, a clinician uses a needle to place a small dissolvable thread at an acupuncture point. The comparison procedure uses the same acupuncture points and a needle, without placing a thread. Both groups take cetirizine.

The researchers plan to enroll 124 adults at three hospitals in Ho Chi Minh City, Vietnam. Participants will be assigned by chance to one of the two groups. They will receive two procedures, two weeks apart. Participants and the people who assess their symptoms will not know which procedure they received. The main assessment compares changes in hives and itching after four weeks. The study will also assess quality of life, a blood marker called total immunoglobulin E, additional antihistamine use, side effects, and whether symptoms return during follow-up through week 8.

Read the detailed description

This multicenter, randomized, sham-controlled, parallel-group trial compares polydioxanone (PDO) thread embedding acupuncture plus cetirizine with sham thread embedding acupuncture plus cetirizine. Eligible adults will complete a 7-day run-in with oral cetirizine 10 mg daily and a daily hives and itch diary. Participants with a 7-day Urticaria Activity Score (UAS7) of at least 16 and a weekly itch score of at least 8 after run-in are eligible for randomization.

The trial plans to randomize 124 participants in a 1:1 ratio using concealed block randomization through REDCap. Participants and outcome assessors are masked to allocation. The statistician will analyze coded groups. Clinicians performing the procedure know the assignment. Procedures are scheduled at baseline and week 2, with a 4-week treatment period and a further 4 weeks of follow-up. The primary analysis compares change from baseline in UAS7 at week 4. Other assessments include UAS7 at weeks 2 and 8, urticaria-related quality of life, serum total IgE, rescue medication use, adverse events, and symptom recurrence. Analyses are planned on an intention-to-treat basis.

02

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

Keywords

  • Chronic Urticaria
  • Thread Embedding Acupuncture
  • Polydioxanone
  • Cetirizine
03

In context

Chronic Urticaria

199 studies on the registry are indexed under Chronic Urticaria; 51 are open to participants now.

This study's planned enrollment of 124 is above the median of 80 across 149 interventional studies indexed under Chronic Urticaria.

Browse Chronic Urticaria studies →

Lead sponsor

University of Medicine and Pharmacy at Ho Chi Minh City is the lead sponsor of 129 studies on the registry; 45 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older and willing to provide written .
  • Chronic urticaria diagnosed according to the EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline. Transient wheals and itching occur at least daily for more than 6 weeks despite prior or current use of an H1 antihistamine, without serious systemic symptoms. Individual wheals resolve within 30 minutes to 24 hours.
  • UAS7 of at least 16 and weekly itch score of at least 8 after the 7-day run-in.
  • No previous thread embedding acupuncture.

Exclusion criteria

Exclusion Criteria:

  • Urticaria with an identified cause, including physical or mechanical urticaria.
  • Warning signs of systemic or autoinflammatory disease (e.g., Schnitzler syndrome or cryopyrin-associated periodic syndromes), or urticarial vasculitis.
  • Cutaneous mast cell disease or erythema multiforme.
  • Current or prior severe associated symptoms such as laryngeal edema, acute angioedema, anaphylaxis, or bradykinin-mediated angioedema including hereditary angioedema.
  • Other chronic pruritic skin disease that could interfere with assessment.
  • History of allergy to implant materials, especially absorbable suture or catgut, or a predisposition to keloid formation.
  • Current or recent therapy or systemic within 2 to 4 weeks (or 30 days) before participation, as specified in the protocol.
  • Biologics such as omalizumab, leukotriene receptor antagonists, or H2 antihistamines within 7 to 14 days before screening or randomization, as specified in the protocol.
  • H1 antihistamine use above the recommended dose within 3 days before screening.
  • Psychotropic medication within the preceding month.
  • or severe endocrine disorder.
  • Serious cardiovascular or cerebrovascular disease, diabetes mellitus, severe hepatic or renal failure, or a hematopoietic disorder.
  • Severe debilitation with reduced immune resistance.
  • Other serious systemic disease, such as systemic lupus erythematosus.
  • Cognitive impairment, psychiatric illness, or a communication barrier that prevents participation in the treatment procedures.
  • A nonabsorbable implant at the intended procedure site.
  • Pregnancy, breastfeeding, or plans to become pregnant during the study.
  • Participation in another clinical trial in the preceding 3 months.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    PDO Thread Embedding Acupuncture Plus Cetirizine

    Participants receive polydioxanone (PDO) thread embedding acupuncture at baseline and week 2, plus oral cetirizine as background treatment.

    Procedure: Polydioxanone Thread Embedding Acupuncture · Drug: Cetirizine 10 mg once daily

  • Sham comparator
    Sham Thread Embedding Acupuncture Plus Cetirizine

    Participants receive a sham procedure at the same acupuncture points at baseline and week 2. The clinician uses an empty needle, so no thread is implanted. Participants also receive oral cetirizine as background treatment.

    Procedure: Sham Thread Embedding Acupuncture · Drug: Cetirizine 10 mg once daily

Interventions

  • ProcedurePolydioxanone Thread Embedding Acupuncture

    An absorbable monofilament polydioxanone (PDO) thread is implanted at seven bilateral acupuncture points (14 sites) at baseline and week 2.

  • ProcedureSham Thread Embedding Acupuncture

    The clinician inserts and withdraws an empty needle at the same acupuncture points at baseline and week 2. The procedure leaves no implanted thread.

  • Both arms receive cetirizine 10 mg orally each morning during the 7-day run-in and 4-week treatment period. Additional cetirizine use for rescue is recorded.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in 7-Day Urticaria Activity Score (UAS7) at Week 4

    UAS7 is the sum of participant-reported daily hive and itch severity scores over seven consecutive days. The total ranges from 0 to 42, with higher scores indicating more severe symptoms. Change is calculated as the follow-up score minus baseline.

    Time frame: Baseline and week 4

Secondary outcomes

  1. Change From Baseline in UAS7 at Weeks 2 and 8

    UAS7 is the sum of participant-reported daily hive and itch severity scores over seven consecutive days. The total ranges from 0 to 42, with higher scores indicating more severe symptoms. Change is calculated as the follow-up score minus baseline.

    Time frame: Baseline and weeks 2 and 8

  2. Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) Score

    Participants complete the disease-specific questionnaire about how chronic urticaria affected their lives in the preceding two weeks. Higher scores indicate greater impairment. Change is calculated as the follow-up score minus baseline.

    Time frame: Baseline and weeks 2, 4, and 8

  3. Change From Baseline in Serum Total Immunoglobulin E (IgE)

    Serum total IgE is measured by enzyme-linked immunosorbent assay (ELISA) and reported in IU/mL. Change is calculated as the week 4 concentration minus baseline.

    Time frame: Baseline and week 4

  4. Proportion of Participants With Adverse Events

    The study records adverse events and serious adverse events in each group during treatment and follow-up. Event severity is graded using the protocol-specified CTCAE criteria.

    Time frame: From baseline through week 8

  5. Proportion of Participants Reporting Recurrence or Flare of Urticaria Symptoms

    Participants are contacted by telephone at week 8 using a standardized script to determine whether symptoms returned or flared during the post-treatment follow-up.

    Time frame: Weeks 4 through 8

  6. Number of Rescue Cetirizine Tablets Used

    The total number of additional cetirizine tablets taken for symptom relief beyond the scheduled background dose is compared between groups.

    Time frame: From baseline through week 4

Other outcomes

  1. Association of Baseline UAS7, Serum Total IgE, and Disease Duration With UAS7 at Week 4

    A multivariable linear regression will estimate the association of each baseline factor with week 4 UAS7, adjusting for study group and site.

    Time frame: Baseline and week 4

07

Study locations

3 sites
  • Ho Chi Minh City Traditional Medicine Hospital, Outpatient Department
    Ho Chi Minh City, Vietnam
  • Le Van Thinh Hospital, Department of Dermatology
    Ho Chi Minh City, Vietnam
  • University Medical Center Ho Chi Minh City, Branch 3
    Ho Chi Minh City, Vietnam
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2027; primary completion for Feb 2029, 19 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Jul 2027
Primary completionEst.
Feb 2029
CompletionEst.
Mar 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07947147
Responsible party
Do Thanh Sang (Lecturer, Faculty of Traditional Medicine, University of Medicine and Pharmacy at Ho Chi Minh City) — Principal investigator
First posted
Nov 18, 2026
Start date
Jul 2027 (estimated)
Primary completion
Feb 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Sang Thanh Do, MD, MSc
Contact
dtsang@ump.edu.vn
+84 948 561 030
Sang Thanh Do, MD, MSc
principal investigator · University of Medicine and Pharmacy at Ho Chi Minh City

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion